Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 25,000 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was bought at an average price of $6.17 per share, for a total transaction of $154,250.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,935,427.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, August 24th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was bought at an average price of $6.24 per share, for a total transaction of $62,400.00.
  • On Wednesday, August 23rd, Phillip Md Et Al Frost bought 12,000 shares of Opko Health stock. The stock was bought at an average price of $6.13 per share, for a total transaction of $73,560.00.
  • On Tuesday, August 22nd, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average price of $6.13 per share, for a total transaction of $11,034.00.
  • On Monday, August 21st, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.10 per share, with a total value of $152,500.00.
  • On Thursday, August 17th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $5.96 per share, with a total value of $298,000.00.
  • On Wednesday, August 16th, Phillip Md Et Al Frost acquired 40,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.04 per share, with a total value of $241,600.00.
  • On Tuesday, August 15th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.08 per share, with a total value of $152,000.00.
  • On Monday, August 14th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.15 per share, with a total value of $61,500.00.
  • On Friday, August 11th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.19 per share, with a total value of $61,900.00.
  • On Thursday, August 10th, Phillip Md Et Al Frost acquired 39,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.23 per share, with a total value of $242,970.00.

Opko Health, Inc. (NASDAQ:OPK) opened at 6.28 on Tuesday. Opko Health, Inc. has a 52-week low of $5.85 and a 52-week high of $12.15. The company’s market cap is $3.51 billion. The firm has a 50-day moving average of $6.24 and a 200 day moving average of $7.11.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The business had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. During the same quarter in the prior year, the business posted $0.02 earnings per share. Opko Health’s revenue was down 12.0% compared to the same quarter last year. Equities research analysts expect that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Opko Health, Inc. (OPK) CEO Phillip Md Et Al Frost Acquires 25,000 Shares of Stock” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/29/opko-health-inc-opk-ceo-phillip-md-et-al-frost-acquires-25000-shares-of-stock.html.

A number of large investors have recently bought and sold shares of OPK. American Asset Management Inc. boosted its stake in Opko Health by 8.8% in the first quarter. American Asset Management Inc. now owns 34,595 shares of the biotechnology company’s stock valued at $277,000 after buying an additional 2,800 shares in the last quarter. Karp Capital Management Corp purchased a new stake in Opko Health during the first quarter valued at $500,000. UBS Asset Management Americas Inc. boosted its stake in Opko Health by 21.1% in the first quarter. UBS Asset Management Americas Inc. now owns 207,127 shares of the biotechnology company’s stock valued at $1,657,000 after buying an additional 36,153 shares in the last quarter. World Asset Management Inc boosted its stake in Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,900 shares in the last quarter. Finally, Boulegeris Investments Inc. boosted its stake in Opko Health by 9.0% in the first quarter. Boulegeris Investments Inc. now owns 130,645 shares of the biotechnology company’s stock valued at $1,045,000 after buying an additional 10,735 shares in the last quarter. 22.46% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on OPK. Cantor Fitzgerald began coverage on shares of Opko Health in a research report on Thursday, August 17th. They set an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Barrington Research boosted their price objective on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $15.28.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.